BioNews Services LLC – Trademark Portfolio
Entity Type: 16
BioNews Services LLC holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 9 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 9 trademarks are registered. Notable registered marks include BIONEWS, WE ARE RARE, SMA NEWS TODAY, BIONEWS SERVICES, and CYSTIC FIBROSIS NEWS TODAY. The owner is based in Pensacola, FL.
3 W. Garden Street, Suite 354
Pensacola, FL 32502
Showing of trademarks Trademarks
Trademark Classifications
BioNews Services LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does BioNews Services LLC have?
BioNews Services LLC has 12 U.S. trademarks filed with the USPTO. Of these, 9 registered, 3 cancelled.
What trademark classes does BioNews Services LLC file in?
BioNews Services LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 42 (Computer & Scientific). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are BioNews Services LLC's most well-known trademarks?
BioNews Services LLC's registered trademark portfolio includes well-known marks such as BIONEWS, WE ARE RARE, SMA NEWS TODAY, BIONEWS SERVICES, and CYSTIC FIBROSIS NEWS TODAY. These are among 9 currently registered trademarks in the portfolio.
What is BioNews Services LLC's trademark registration success rate?
BioNews Services LLC has a 75% trademark registration rate, with 9 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.